Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.
about
Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathwayFluoropyrimidine ActivityMicroarray-based gene expression profiling to elucidate effectiveness of fermented Codonopsis lanceolata in mice.The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell linesThe colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information.Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells.A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells.TGM2: a cell surface marker in esophageal adenocarcinomas.Defining new criteria for selection of cell-based intestinal models using publicly available databases.Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice.Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variantsAutonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone.Calretinin mediates apoptosis in small cell lung cancer cells expressing tetraspanin CD9.DNA microarrays in herbal drug researchGene signatures of drug resistance predict patient survival in colorectal cancerMacrophage inhibitory cytokine-1 (MIC-1/GDF15) gene deletion promotes cancer growth in TRAMP prostate cancer prone miceOxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance.Identification of reproducible drug-resistance-related dysregulated genes in small-scale cancer cell line experiments.Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29.Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.MiR-320e is a novel prognostic biomarker in colorectal cancer.Routes of Ca2+ Shuttling during Ca2+ Oscillations: FOCUS ON THE ROLE OF MITOCHONDRIAL Ca2+ HANDLING AND CYTOSOLIC Ca2+ BUFFERSIdentifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissuesOxaliplatin in the treatment of colorectal cancer.Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer.DNA microarray reveals different pathways responding to paclitaxel and docetaxel in non-small cell lung cancer cell line.Predictive and prognostic markers in colorectal cancer.A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI.Approaches to biomarkers in human colorectal cancer: looking back, to go forward.Wnt-β-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer.NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.Implementing prognostic and predictive biomarkers in CRC clinical trials.The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe?Gene expression profiling of human hepatoblastoma using archived formalin-fixed and paraffin-embedded tissues.Promoter demethylation of nuclear factor-erythroid 2-related factor 2 gene in drug-resistant colon cancer cells.Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator.Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy.Translational control analysis by translationally active RNA capture/microarray analysis (TrIP-Chip).Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy.
P2860
Q28478265-5A24F441-F331-47E1-A2B0-C16A862491F4Q29883401-CF209C59-0839-478E-ABE2-258A26FC4B88Q33580529-85463CDC-85B0-4E2E-BD4C-8A7374AE0D3DQ33732552-7E3513FC-6825-4C37-9B8F-4CC21D0A2D49Q33776217-3F430DFA-9616-422D-AD98-04A7ABE9F107Q33979225-D5F21657-A7DE-4813-B323-6D9D03D1D83DQ34043011-DC9CF55E-F0D8-445F-BEF9-6E932AD5B05FQ34219975-F3066F05-06BA-4C3D-840A-3F9D0AD4A356Q34314896-1ACFBB1E-FC63-45B8-9166-428EA0102076Q34405669-02797DC9-E7E6-40A2-BBE3-243A3C4924E9Q34525850-E270447D-01DA-4F65-85A5-8079D208BDA8Q34680692-9F0FDC0D-C1C7-4E87-AA4A-F6E8C3802A98Q34774711-3659A61B-3D41-4FF0-90F1-FA768D5D7FF1Q35219881-2164DDBF-8775-49D2-975E-74D09E4A2B2EQ35237150-46379474-555A-4922-B54E-16F5FB5E00C5Q35563909-612DABE8-F042-4D9A-91E4-DFEEA333CF90Q35572923-C17EDDFE-95A7-4453-8633-63C69B010258Q35851987-E3A2F152-82E7-4440-964A-2B72FD01B5EAQ36097117-63503D37-DCCB-41BA-9D3E-DF308DAFD025Q36193189-8CCB6B80-D0F7-4D9A-BF03-1366120611B5Q36286673-946F6FA8-6861-440B-961E-6CE082F0E140Q36301279-5152E2A1-9B47-4B74-8242-4B1E9BF0EB9BQ36562337-DACF6EE1-3A1D-41FA-BF73-BFD6548348E5Q36788436-558BAB5B-0627-4428-9009-CF22EB1D54A5Q36842791-39383D9B-34EC-4C98-BB51-4DE46571D7DCQ37054550-886E6C0C-C373-456A-BC43-F56E8FB51DBAQ37073444-3AC11480-1102-4BEC-812B-0DBC43211EF9Q37082526-AD62007F-0370-4277-BDED-36E09200146DQ37358420-EABB1AA7-C63A-480A-9808-EBFB62CF4104Q37544377-7FF78A38-72C2-411B-9CD6-98D458C51624Q37687793-6EF180D7-04EC-41E3-A1D8-46C437EF10CCQ37842126-9E877543-3D2D-4F3A-A5DF-58CD965D652BQ38068040-C4DFB9FA-284C-4E06-85CF-C7443C24CCD5Q38411627-CE81BB98-625D-42AB-BA95-1BA02A26112AQ38815478-1945BC39-DC0F-43BA-ACC4-C186CC865198Q39229225-B12CB696-D6B7-406A-8F38-AF0A22D3B270Q39387335-460E532C-32CC-4BCF-904B-579F3560933AQ39590420-4CE31D93-24FE-4468-97F5-D56B58B4517DQ39745242-7F5B1266-D263-4734-9A21-E147F0386BACQ39786191-462CF35C-AE36-4117-8728-FC51E78FA435
P2860
Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Pharmacogenomic identification ...... chemotherapy in colon cancer.
@en
Pharmacogenomic identification ...... chemotherapy in colon cancer.
@nl
type
label
Pharmacogenomic identification ...... chemotherapy in colon cancer.
@en
Pharmacogenomic identification ...... chemotherapy in colon cancer.
@nl
prefLabel
Pharmacogenomic identification ...... chemotherapy in colon cancer.
@en
Pharmacogenomic identification ...... chemotherapy in colon cancer.
@nl
P2093
P1433
P1476
Pharmacogenomic identification ...... o chemotherapy in colon cancer
@en
P2093
Andrea McCulla
Carlos Caldas
Daniel B Longley
Estelle G McLean
John Boyer
Patrick G Johnston
Peter M Wilson
Wendy L Allen
P304
P356
10.1158/0008-5472.CAN-05-2693
P407
P577
2006-03-01T00:00:00Z